RESEARCH PROJECT IN T CELL REPERTOIRE

The aim of this research project is to evaluate the T-cell repertoire diversity of the CD8 T-cell response emerging during chronic viral infections in order to determine whether structural signatures of immune response are associated with virus control.

2002-2003: Project’s leader, I.N.S.E.R.M, Gustave Roussy Institute, Paris, France Research project: "Development of candidate vaccines for the immunotherapy of cancer". 1998-2001: Post-doc, Ludwig Institute for Cancer Research, Lausanne, Switzerland. Research project: "Preclinical study of the role of adjuvants in potentiating the CD8 response specific for tumor antigens". 1995-1997 Post-doc, Department of Immunology and Blood Bank, Leiden University Hospital, The Netherlands. 1994: PhD thesis, University Pierre and Marie Curie, Paris, France.

Selected publications:

• Miconnet I. and Pantaleo G. A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response. Vaccine 2008, 26:4006-4014.
   
• Gross D.-A., Graff-Dubois S., Opolon P., Cornet S., Alves P., Bennaceur-Griscelli A., Faure O., Guillaume P., Firat H., Chouaib S., Lemonnier F.A., Davoust J., Miconnet I., Vonderheide R.H. and Kosmatopoulos K. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J. Clin. Invest. 2004, 113:425-433.
   
• Esslinger C., Chapatte L., Finke D., Miconnet I., Guillaume P., Lévy F., and MacDonald H.R. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8⁺ T cell responses. J. Clin. Invest. 2003, 111:1673-1681.
   
• Miconnet I., Koenig S., Krieg A., Guillaume P., Cerottini J.-C. and Romero P. CpG are efficient adjuvants for specific CTL induction against tumor antigen derived peptide. J. Immunol. 2002, 168:1212-1218.£
   
• Miconnet I., Coste I., Beerman F., Haeuw J.-F., Cerottini J.-C., Bonnefoy J.-Y., Romero P. and Renno T. Cancer vaccine design: a novel bacteria adjuvant for peptide specific CTL induction. J. Immunol. 2001, 166:4612-4619.
   
• Jeannin, P., Renno T., Goetsch L., Miconnet I., Aubry J.P., Delneste Y., Herbault N., Baussant T., Magistrelli G., Soulas C., Romero P., Cerottini J.-C. and Bonnefoy J.-Y. OmpA targets dendritic cells, induces their maturation and antigen delivery into the MHC class I presentation pathway. Nat. Immunol. 2000, 1:502-509.
   
• Miconnet I., Servis C., Cerottini J.-C., Romero P. and Lévy F. Amino acid identity and/or position determines the proteasomal cleavage of the HLA-A*0201-restricted peptide tumor antigen MAGE-3_271-279. J. Biol. Chem. 2000, 275:26892-26897.